Results 1 to 10 of about 6,848 (153)

Immunomodulatory Effects Associated with Cladribine Treatment

Cells, 2021
Cladribine is a synthetic deoxyadenosine analogue with demonstrated efficacy in patients with relapsing-remitting multiple sclerosis (MS). The main mechanism of action described for cladribine is the induction of a cytotoxic effect on lymphocytes ...
Herena Eixarch, Carmen Espejo, Xavier Montalbán   +2 more
exaly   +3 more sources

Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs [PDF]

Therapeutic Advances in Neurological Disorders
Background: Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva ® (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines ® (US) are nurse–pharmacy-led PSPs ...
Jiwon Oh, Mavis Ayer, Raed Alroughani, Samar Farouk, Mounir Khoury, Sabrina de Souza, Michela Bossolasco, Kate Morgan, Laura Negrotto, Tracey Quinn, Amir Boshra, Joseph Youssef, Murad Al-Naqshbandi, Kelly MacDonald, Meritxell Sabidó, Jeffrey M. Muir, Berenice Silva   +16 more
doaj   +2 more sources

Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations [PDF]

Therapeutic Advances in Neurological Disorders
Background: Autoimmune (AI) comorbidities are common in people with multiple sclerosis (MS) and may complicate therapeutic management, particularly when dual immunosuppression is required.
Vito A. G. Ricigliano, Ines Masmoudi, Marine Boudot de la Motte, Eric Manchon, Jérôme De Seze   +4 more
doaj   +2 more sources

Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis [PDF]

BMC Neurology
Background Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system through persistent inflammation and demyelination.
Hind Alnajashi, Hussain Ali J Almohammed, Ahmed Salah Morad, Bushra Wadi Bin Saddiq, Kawthar Faisal Kushara, Bayan Mohammed Khair Al Zoabi, Wejdan Ahmed Aldawsari, Fatimah Ibrahim Almuhaysin, Mayar Ahmed Gasim, Hams Akram Alharbi, Tanveer Nidal Khan   +10 more
doaj   +2 more sources

Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort [PDF]

Neurotherapeutics
Anti-CD20 antibodies and cladribine are established therapies for active relapsing multiple sclerosis (RMS). Increasing evidence suggests that switching between these therapies may be beneficial in patients with ongoing disease activity under current ...
Franz Felix Konen, Steffen Pfeuffer, Konstantin Fritz Jendretzky, Klaus Gehring, Birte Elias-Hamp, Kurt-Wolfram Sühs, Stephan Halle, Korbinian Brand, Ralf Lichtinghagen, Eline Willemse, Marc Pawlitzki, Jens Kuhle, Sven G. Meuth, Christoph Kleinschnitz, Refik Pul, Thomas Skripuletz   +15 more
doaj   +2 more sources

NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital [PDF]

Frontiers in Neurology
BackgroundCladribine is an immunomodulatory agent used in the treatment of relapsing–remitting multiple sclerosis (MS) and, in some countries, for active progressive forms of MS.
Nora Berg Bjørnevoll, Karl Bjørnar Alstadhaug, Karl Bjørnar Alstadhaug   +2 more
doaj   +2 more sources

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

Cells, 2023
Cladribine has been approved for the treatment of multiple sclerosis (MS) and its administration results in a long-lasting depletion of lymphocytes. As lymphopenia is known to hamper immune responses to vaccination, we evaluated the immunogenicity of the
Leoni Rolfes, Steffen Pfeuffer, Jelena Skuljec, Xia He, Chuanxin Su, Sinem-Hilal Oezalp, Marc Pawlitzki, Tobias Ruck, Melanie Korsen, Konstanze Kleinschnitz, Derya Aslan, Tim Hagenacker, Christoph Kleinschnitz, Sven G. Meuth, Refik Pul   +14 more
doaj   +1 more source

Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

Frontiers in Immunology, 2022
Cladribine (2-chlorodeoxyadenosine, 2CdA) is one of the most effective disease-modifying drugs for multiple sclerosis (MS). Cladribine is a synthetic purine nucleoside analog that induces cell death of lymphocytes and oral cladribine treatment leads to a
Tiago Medeiros-Furquim, Tiago Medeiros-Furquim, Sinan Ayoub, Laura J. Johnson, Andrea Aprico, Eze Nwoke, Michele D. Binder, Michele D. Binder, Trevor J. Kilpatrick, Trevor J. Kilpatrick   +9 more
doaj   +1 more source

Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System

Pharmaceuticals, 2023
Background. Cladribine belongs to the group of disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS). According to the highlights of a meeting held by the Pharmacovigilance Risk Assessment Committee (PRAC) on 14 January 2022 ...
Elena Mirabela Velișcu, Valerio Liguori, Antonietta Anatriello, Giorgia Teresa Maniscalco, Andrea Cantone, Luigi Di Costanzo, Pasquale Stefanelli, Cristina Scavone, Annalisa Capuano   +8 more
doaj   +1 more source

Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis

Journal of Neuroinflammation, 2022
Background Cladribine is a synthetic purine analogue that interferes with DNA synthesis and repair next to disrupting cellular proliferation in actively dividing lymphocytes.
Christina B. Schroeter, Leoni Rolfes, K. S. Sophie Gothan, Joel Gruchot, Alexander M. Herrmann, Stefanie Bock, Luca Fazio, Antonia Henes, Venu Narayanan, Steffen Pfeuffer, Christopher Nelke, Saskia Räuber, Niklas Huntemann, Eduardo Duarte-Silva, Vera Dobelmann, Petra Hundehege, Heinz Wiendl, Katharina Raba, Patrick Küry, David Kremer, Tobias Ruck, Thomas Müntefering, Thomas Budde, Manuela Cerina, Sven G. Meuth   +24 more
doaj   +1 more source